View Older Stories View More Recent Stories
-
NVIDIA partners with Lilly for $1 billion AI drug discovery lab
-
Abivax shares trim gains after French Finance Ministry statement
-
Abivax shares surge after report flags continued Eli Lilly takeover interest
-
Schrodinger Inc. (SDGR) Partners with Lilly to Make TuneLab Platform Available in LiveDesign
-
Lilly's combined Taltz and Zepbound therapy shows promise in psoriatic arthritis
-
Eli Lilly & Co. (LLY) calls more active than puts into the annual J.P. Morgan Healthcare Conference
-
Bernstein: 'This Is a Good Deal for Eli Lilly (LLY)'
-
Eli Lilly (LLY) Reiterated at Overweight by Cantor Fitzgerald
-
Lilly to acquire Ventyx Biosciences for $1.2 billion in cash
-
UBS Assumes Eli Lilly (LLY) at Buy
-
After-hours movers: Strategy, Mobileye, Ventyx Bioscience, Praxis
-
Ventyx Biosciences (VTYX) halted on volatility following WSJ report
-
Eli Lilly & Co. (LLY) Nears Deal for Ventyx Biosciences (VTYX) - WSJ
-
Analysts expect this mega-cap pharma stock to outperform this year
-
Eli Lilly (LLY) PT Raised to $1,234 at Leerink Partners
-
Goldman Sachs: 'top themes we're tracking for 2026'
-
Abivax soars on report of Eli Lilly meeting French officials over possible deal
-
Here's the list of top biotech stocks to own for 2026
-
Trump to announce prescription drug price agreements
-
Bernstein on Eli Lilly (LLY): Orforglipron De-Risks the Oral GLP-1 Path
-
RBC: 'We have just confirmed that a recent clinicaltrials.gov listing for a new drug called BIIB145'
-
Leerink on Eli Lilly (LLY): 'Orforglipron Delivers Weight Maintenance Following Injectables'
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Goldman Sachs Reiterates Buy Rating on Eli Lilly (LLY)
-
BofA Comments on GLP-1s and Potential Pressure Ahead
-
Daiwa Securities Upgrades Eli Lilly (LLY) to Buy (1)
-
Lilly reports updated breast cancer drug data at medical conference
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY) Following Topline Results
-
BMO Capital on Eli Lilly (LLY): 'A True TRIUMPH'
-
FDA reportedly pressing for reviewers to speed up evaluation of Eli Lilly's weight-loss pill
-
Eli Lilly stock climbs after retatrutide delivers massive weight loss in trial
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly plans $6 billion Alabama manufacturing facility
-
Lilly completes Adverum acquisition for $3.56 per share plus CVRs
-
Lilly's Jaypirca reduces cancer progression risk by 80% in study
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield
-
Nobel laureate Carolyn Bertozzi rejoins Eli Lilly board
-
Eli Lilly (LLY) PT Raised to $1,200 at BMO Capital
-
Eli Lilly (LLY) PT Raised to $1,163 at Guggenheim
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Raised to $950 at Berenberg
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Raised to $1,286 at BofA Securities, 'Remains in the GLP1 driver's seat'
-
Eli Lilly reduces Zepbound prices on direct platform
-
Eli Lilly's (LLY) Zepbound Reached All-Time High on TRx and NRx- Cantor Fitzgerald
-
What comes next for Eli Lilly (LLY) stock after $1T valuation?
-
Bernstein on IRA pricing: $245 really is the floor
-
Lilly to present breast cancer drug trial results at December symposium
-
Bernstein on Novo's Alzheimer's miss: 'Don't expect Lilly to stay quiet'
